Barrington Research Raises PT to $290, Maintains Outperform Rating

Barrington Research Raises PT to $290, Maintains Outperform Rating

Barrington Research has updated its price target for ResMed Inc. (RMD) to $290, maintaining an "Outperform" rating. The move reflects a bullish outlook on the company's financial prospects and growth prospects. This update comes after ResMed reported its fiscal Q4 2025 earnings, which exceeded market expectations. The company posted non-GAAP earnings per share (EPS) of $2.55 and net revenue of $1.35 billion, surpassing analyst estimates [1].

ResMed's strong performance in the latest quarter has been driven by robust demand for its sleep devices. The company's Chief Commercial Officer, Bobby Ghoshal, resigned effective August 1, 2025, but the company has not disclosed any immediate impact on operations. Additionally, ResMed has been seeking tuck-in acquisitions to enhance its product offerings and market presence [1].

Analysts from various firms have also adjusted their price targets for ResMed in recent weeks. JPMorgan and Baird have increased their targets to $310 and $305, respectively, while Piper Sandler and Stifel have maintained their targets at $270. KeyBanc and Jefferies have raised their targets to $298 and $290, respectively, while Wolfe has lowered its target to $215. UBS has increased its target to $325, and RBC Capital has set its target at $300 [1].

The positive sentiment around ResMed is reflected in the company's share price, which has been trading higher despite the resignation of its Chief Commercial Officer. The company's financial health and growth prospects continue to be a focus for investors and analysts alike. ResMed's strong performance in the latest quarter and the positive outlook from analysts suggest that the company is well-positioned for future growth.

References:
[1] https://www.marketscreener.com/news/resmed-cfo-chief-legal-officer-sells-shares-ce7c5edad981f52d
[2] https://www.marketbeat.com/instant-alerts/barrington-research-has-bullish-outlook-for-para-q2-earnings-2025-08-01/